ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 153.1 EUR | -0.05% |
|
-3.43% | +9.26% |
| 07-05 | Sector Update: Health Care Stocks Steady Premarket Friday | MT |
| 07-05 | AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook | MT |
| Sales 2024 * | 55.2B 50.94B 4,310B | Sales 2025 * | 58.2B 53.7B 4,544B | Capitalization | 295B 273B 23,059B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.6B 7.94B 672B | Net income 2025 * | 11.44B 10.55B 893B | EV / Sales 2024 * | 6.38 x |
| Net Debt 2024 * | 56.89B 52.49B 4,442B | Net Debt 2025 * | 47.91B 44.21B 3,740B | EV / Sales 2025 * | 5.9 x |
| P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
22.9
x | Employees | 50,000 |
| Yield 2024 * |
3.73% | Yield 2025 * |
3.89% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | -0.05% | ||
| 1 week | -3.43% | ||
| Current month | -3.43% | ||
| 1 month | -0.70% | ||
| 3 months | -2.50% | ||
| 6 months | +3.22% | ||
| Current year | +9.26% |
1 week
151.44
160.02
1 month
151.44161.72
Current year
140.20168.92
1 year
118.80168.92
3 years
90.00168.92
5 years
57.80168.92
10 years
41.00168.92
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 53 | 31/12/11 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 31/12/12 |
Richard Gonzalez
CHM | Chairman | 70 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 31/12/12 |
Edward Rapp
BRD | Director/Board Member | 66 | 31/12/12 |
| Director/Board Member | 70 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/07/24 | 153.1 | -0.05% | 1,020 |
| 04/07/24 | 153.2 | +0.59% | 77 |
| 03/07/24 | 152.3 | -2.43% | 77 |
| 02/07/24 | 156.1 | -2.08% | 768 |
| 01/07/24 | 159.4 | +0.54% | 636 |
Delayed Quote Xetra, July 05, 2024 at 04:35 pm
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
14/07/2024
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
167.2
USD
Average target price
183.2
USD
Spread / Average Target
+9.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
